Evidence map›Paper›PMID 26369969›Full record

ArticleAntimicrobial agents and chemotherapy2015

Assessment of Antiviral Properties of Peramivir against H7N9 Avian Influenza Virus in an Experimental Mouse Model.

Amber Farooqui, Linxi Huang, Suwu Wu, Yingmu Cai, Min Su, Pengzhou Lin, Weihong Chen, Xibin Fang, Li Zhang, Yisu Liu and 5 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Antimicrobial agents and chemotherapy, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Article
  2. Article
  3. Review
  4. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors.

Amber FarooquiDivision of Immunology, International Institute of Infection and Immunity, University Health Network & Shantou University Medical College, Shantou, China Division of Experimental Therapeutics, Toronto General Hospital Research Institute, University Health Network, Toronto, Ontario, Canada Guangdong Provincial Key Laboratory of Infectious Diseases and Molecular Immunopathology, Shantou, Guangdong, China.
Linxi HuangInfectious Diseases Department, The First Affiliated Hospital of Shantou University Medical College, Shantou, China.
Suwu WuIntensive Care Unit, Shantou Central Hospital, Shantou, China.
Yingmu CaiDepartment of Laboratory Medicine, The First Affiliated Hospital of Shantou University Medical College, Shantou, Guangdong, China.
Min SuDepartment of Pathology, Shantou University Medical College, Shantou, China.
Pengzhou LinInfectious Diseases Department, The First Affiliated Hospital of Shantou University Medical College, Shantou, China.
Weihong ChenIntensive Care Unit, Shantou Central Hospital, Shantou, China.
Xibin FangIntensive Care Unit, Shantou Central Hospital, Shantou, China.
Li ZhangDivision of Immunology, International Institute of Infection and Immunity, University Health Network & Shantou University Medical College, Shantou, China.
Yisu LiuDivision of Immunology, International Institute of Infection and Immunity, University Health Network & Shantou University Medical College, Shantou, China.
Tiansheng ZengDivision of Immunology, International Institute of Infection and Immunity, University Health Network & Shantou University Medical College, Shantou, China.
Stephane G PaquetteDivision of Experimental Therapeutics, Toronto General Hospital Research Institute, University Health Network, Toronto, Ontario, Canada Institute of Medical Science, Faculty of Medicine, University of Toronto, Toronto, Ontario, Canada.
Adnan KhanDivision of Immunology, International Institute of Infection and Immunity, University Health Network & Shantou University Medical College, Shantou, China Guangdong Provincial Key Laboratory of Infectious Diseases and Molecular Immunopathology, Shantou, Guangdong, China.
Alyson A KelvinDivision of Experimental Therapeutics, Toronto General Hospital Research Institute, University Health Network, Toronto, Ontario, Canada.
David J KelvinDivision of Immunology, International Institute of Infection and Immunity, University Health Network & Shantou University Medical College, Shantou, China Division of Experimental Therapeutics, Toronto General Hospital Research Institute, University Health Network, Toronto, Ontario, Canada Guangdong Provincial Key Laboratory of Infectious Diseases and Molecular Immunopathology, Shantou, Guangdong, China Institute of Medical Science, Faculty of Medicine, University of Toronto, Toronto, Ontario, Canada Department of Immunology, Faculty of Medicine, University of Toronto, Toronto, Ontario, Canada dkelvin@jidc.org.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The H7N9 influenza virus causes a severe form of disease in humans. Neuraminidase inhibitors, including oral oseltamivir and injectable peramivir, are the first choices of antiviral treatment for such cases; however, the clinical efficacy of these drugs is questionable. Animal experimental models are essential for understanding the viral replication kinetics under the selective pressure of antiviral agents. This study demonstrates the antiviral activity of peramivir in a mouse model of H7N9 avian influenza virus infection. The data show that repeated administration of peramivir at 30 mg/kg of body weight successfully eradicated the virus from the respiratory tract and extrapulmonary tissues during the acute response, prevented clinical signs of the disease, including neuropathy, and eventually protected mice against lethal H7N9 influenza virus infection. Early treatment with peramivir was found to be associated with better disease outcomes.

Indexed as

Acids, CarbocyclicAnimalsAntiviral AgentsCyclopentanesDogsDrug Administration ScheduleEnzyme InhibitorsFemaleGuanidinesHumansInfluenza A Virus, H7N9 SubtypeInjections, IntramuscularLungMadin Darby Canine Kidney CellsMiceMice, Inbred C57BLAcids, CarbocyclicAntiviral AgentsCyclopentanesEnzyme InhibitorsGuanidinesNeuraminidaseOseltamivirperamivirViral Proteins

Identifiers

PMID26369969
PMCPMC4649212

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-SA
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.